Biosimilar Products in Rheumatoid Arthritis: Role of the Pharmacist

Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP;

Biosimilar Products in Rheumatoid Arthritis: Role of the Pharmacist

March 30, 2017

Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP

Pharmacy Times, March 2017 Central Nervous System, Volume 83, Issue 3

This Continuing Education activity is supported by an educational grant from Sandoz, Inc.

This activity is supported by an educational grant from Sandoz, Inc.

Faculty

Geoffrey C. Wall, PharmD, FCCP, BCPS, CGPProfessor of Clinical SciencesDrake University College of Pharmacy and Health SciencesDes Moines, IAThomas J. Cook, PhD, RPhDirector of Graduate EducationGlobalscope IncNew York, NYFreelance Medical Writer

Educational Objectives

After completing this continuing education program, the participant will be able to:

Examine the changing landscape of rheumatoid arthritis (RA) biosimilar products.
Explain the potential impact of RA biosimilar products on their practice.
Identify strategies to address barriers to the use of RA biosimilar products.

Target audience: Pharmacists

Type of activity: Knowledge or Application (select one)

Release date: March 15, 2017

Expiration date: March 15, 2018

Estimated time to complete activity: 2.0 hours

Fee: Free

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-17-013-H01-P. The activity is available for CE credit through March 15, 2018.